mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA -Mutant Breast Cancer
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Persistent mTORC1 signaling correlates with resistance to PI3K p110α inhibition in breast cancer, which can be overcome by inhibiting mTORC1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Previous studies by other groups have also demonstrated the importance of mTORC1 inhibition for the effectiveness of MAPK or PI3K-pathway directed therapies in diverse tumor-types including lung, breast and melanoma39–42.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
She, Q.-B., Chandarlapaty, S., Ye, Q., Lobo, J., Haskell, K. M., Leander, K. R., DeFeo-Jones, D., Huber, H. E., & Rosen, N. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003065 · Cited by 301
Self-citationRetractedNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“Table 2 displays the breast tumor subtype, the BYL719 dose, the type of PIK3CA mutation, the amount of pS6 by H-score, the best tumor response to therapy by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (28), and the tumor Fig.”
MethodmTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621 · cited 1×
“The phosphatidylinositol 3-kinase (PI3K) pathway, which includes the PI3K holoenzyme and the downstream effectors Akt and mammalian target of rapamycin (mTOR), is essential for cell growth, proliferation, survival, and metabolism (1, 2).”
BackgroundHigh Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330 · cited 1×
“The phosphatidylinositol 3-kinase (PI3K) pathway, which includes the PI3K holoenzyme and the downstream effectors Akt and mammalian target of rapamycin (mTOR), is essential for cell growth, proliferation, survival, and metabolism (1, 2).”
BackgroundSelf-citationEverolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Self-citationTargeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445 · cited 1×
“The PI3K family of enzymes is divided into three main classes (classes I to III), with class I being the most often implicated in human cancer (3, 4).”
BackgroundSelf-citationExploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185 · cited 1×
“The PI3K family of enzymes is divided into three main classes (classes I to III), with class I being the most often implicated in human cancer (3, 4).”
BackgroundDebnath, J., Muthuswamy, S. K., & Brugge, J. S. (2003) · Methods · doi:10.1016/s1046-2023(03)00032-x · Cited by 1,995 · cited 2×
“IF and confocal microscopy 3D structures were fixed and stained as described (49).”
Method
Research works printed but not linked: 1
- Kim P. S., Von Ahsen O., Schmitz A., Schatz C., Magonova K., Lee T., Harvie G., Barham R., Leesman G., Kuller A., Lin F., Gong H., Krahn T., Singh S., Pathway profiling of signal transduction proteins in paired tumor and adjacent normal tissues obtained from breast cancer patients. Cancer Res. 70 (2010).
Cited by
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
“Persistent mTORC1 activity in PIK3CA mutant breast cancer cell lines was responsible for resistance to the p110a-selective inhibitor alpelisib (BYL719; Table S1) and was reversed by combination with the mTORC1 inhibitor everolimus (Elkabets et al., 2013).”
BackgroundPI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0954-x · Cited by 1,520
“BYL719 (alpelisib), an oral selective PI3Kα isoform inhibitor, exhibited dose-dependent antitumor activity in tumor xenograft models, particularly models with mutated or amplified PIK3CA, highlighting the potential antitumor activity of alpelisib in patients with PIK3CA-altered tumors [151, 152].”
BackgroundArdito, F., Giuliani, M., Perrone, D., Troiano, G., & Muzio, L. L. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3036 · Cited by 1,336
“Signaling networks in which protein kinases operate are highly complex, but we believe that understanding the regulatory functions of kinases may be a valid means to identify more effective therapies against cancer (146,147).”
Metadata
- Authors
- Elkabets, M., Vora, S., Juric, D., Morse, N., Mino-Kenudson, M., Muranen, T., Tao, J., Campos, A. B., Rodon, J., Ibrahim, Y. H., Serra, V., Rodrik-Outmezguine, V., Hazra, S., Singh, S., Kim, P., Quadt, C., Liu, M., Huang, A., Rosen, N., Engelman, J. A., Scaltriti, M., & Baselga, J.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Massachusetts General Hospital (US)
- Harvard University (US)
- Vall d'Hebron Institute of Oncology (ES)
- Prometheus Therapeutics & Diagnostics, 9410 Carroll Park Drive, San Diego, CA 92121, USA.
- Novartis (Switzerland) (CH)
- Oncology Translational Medicine, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
- Human Oncology & Pathogenesis Program and Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA.
- Corresponding author
- Scaltriti, Maurizio
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2013-07-31
- Volume
- 5
- Issue
- 196
- Pages
- 196ra99-196ra99
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC3935768
- OpenAlex
- W2153096480
- Cited by
- 332
- References
- 50
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 33 · 2023: 18 · 2022: 13 · 2021: 34 · 2020: 33 · 2019: 32 · 2018: 16 · 2017: 27 · 2016: 34 · 2015: 34 · 2014: 29 · 2013: 7
- FWCI
- 15.54
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- National Cancer Institute (K99CA180221, R01CA137008)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- mTORC1 inhibition, PIK3CA mutation, breast cancer, alpelisib, everolimus, drug resistance, Akt phosphorylation, insulin-like growth factor I, neuregulin-1, combination therapy, mTOR signaling
- MeSH terms
- Everolimus, Mechanistic Target of Rapamycin Complex 1, Phosphoinositide-3 Kinase Inhibitors, Adult, Animals, Breast Neoplasms, Female, Humans, Insulin-Like Growth Factor I, Middle Aged, Mutation, Treatment Outcome, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Sirolimus, Inhibitory Concentration 50, Neuregulin-1, Ribosomal Protein S6, Cell Line, Tumor, Multiprotein Complexes, Protein Kinase Inhibitors, Mice, Class I Phosphatidylinositol 3-Kinases, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA -Mutant Breast Cancer. https://app.cochat.ai/papers/10.1126/scitranslmed.3005747
- The paper
- Elkabets, M., Vora, S., Juric, D., Morse, N., Mino-Kenudson, M., Muranen, T., Tao, J., Campos, A. B., Rodon, J., Ibrahim, Y. H., Serra, V., Rodrik-Outmezguine, V., Hazra, S., Singh, S., Kim, P., Quadt, C., Liu, M., Huang, A., Rosen, N., . . . Baselga, J. (2013). mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA -Mutant Breast Cancer. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.3005747
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.